GMAC Launches 'Study in China' Initiative in Partnership with 11 Leading Business Schools in China
BEIJING and HONG KONG, June 22, 2018 (GLOBE NEWSWIRE) -- On June 22, the Graduate Management Admission Council (GMAC) joins hands with 11 leading business schools in China to launch the "Study in China" initiative. This partnership marks the opening of an interactive platform for international students across 20 Belt and Road (B&R) regions to explore opportunities in China and to pursue higher education in business-related fields. The "Study in China" initiative aims to meet rapidly growing international student demand and to champion China as a world-class study destination and emerging global hub for business education.
The "Study in China" online portal (www.studyinchinamba.com) officially launched today allows students to discover more about studying and living in China. The newly designed English-language website connects prospective students with partner business schools and offers access to an abundance of information to help find the perfect fit for their China education experience. GMAC's gateway guides international applicants from these Belt and Road regions in Asia, the Middle East, Africa, and Europe through the necessary steps to begin a new learning chapter in one of the most dynamic economies in the world. It offers in-depth information and insider advice on the schools and programs available, including international program structure, syllabus overview, admission requirements, application times, campus facilities, scholarships and financial aid. Students can also opt-in to conveniently contact the schools for further detail via GMAC's one-stop portal.
To offer a glimpse into the great opportunities available, GMAC is organizing a "Study in China" contest from June 22 to August 31. Participants submit short essays about why they want to study in China to win a round-trip to China. Three selected winners will be awarded return economy flights and campus accommodation to visit preferred business schools and enjoy a first-hand experience of the school and campus life.
The new initiative partners with China's most prestigious business schools located in Beijing, Shanghai, and Hong Kong. The top-ranked institutions include Antai College of Economics and Management, Shanghai Jiao Tong University; China Europe International Business School; CUHK Business School, The Chinese University of Hong Kong; School of Management, Fudan University; HKUST Business School, The Hong Kong University of Science and Technology; Guanghua School of Management, Peking University; Business School, Renmin University of China; School of Economics and Management, Tsinghua University; BiMBA Business School of the National School of Development, Peking University; Cheung Kong Graduate School of Business; and HKBU School of Business, Hong Kong Baptist University.
Mr. Sangeet Chowfla, the President and CEO of GMAC, announced GMAC's pride in creating more opportunities for prospective students to access business education. He believes "This will effectively connect international talent with the right opportunities to excel at China's leading business schools and programs, while offering students all around support during the study abroad period." Mr. Chowfla emphasized GMAC's observations over the past few years, as China holds the potential "to become one of the most popular study destinations." This "Study in China" initiative, according to Chowfla, intends to further raise the profile of business schools in China and showcase the value of business education to international candidates.
Professor Lu Xiongwen, Dean of the School of Management at Fudan University, expressed his congratulations on the launch of the new initiative and extended a warm welcome to prospective students looking to come study in China. He quoted an old Chinese proverb that says, "Practice goes deeper than theoretic knowledge," indicating that these programs would open new doors of understanding. "I believe this learning journey will present you a broad picture of China's economic trends at present and future, the uniqueness of Chinese business models as well as different features of the Chinese market and global market," said Prof. Lu. "You will also enjoy the opportunity of learning about and appreciating China's profound culture immersed in thousands of years of history."
Professor Kar Yan Tam, Dean of the HKUST Business School, also commented on the initiative, saying that "China will remain the world's major growth engine in the years ahead, with reforms to allow its economy to unleash new potential and the Belt and Road initiative to bring a sustained momentum to the region." He also highlighted that "Students should not only receive the best international business education to develop a global perspective, but also look for opportunities to experience the vitality of China. Hong Kong is a dynamic and international city where students can enjoy access to a unique fusion of East and West. The city also stays at the forefront of business education and offers different enriching and diverse learning experiences to prepare students for a flourishing career in China and beyond."
The "Study in China" initiative exemplifies GMAC's consistent efforts in promoting business education around the world. This network acts as a bridge within the B&R community to empower students' professional journeys as future business leaders and entrepreneurs in China and abroad.
About GMAC: The Graduate Management Admission Council (GMAC) is a global, non-profit association of leading graduate business schools. Founded in 1953, we are committed to creating solutions for business schools and candidates to better discover, evaluate and connect with each other. We work on behalf of the schools and the graduate management education community, as well as guide candidates on their journey to higher education, to ensure that no talent goes undiscovered.
GMAC provides world-class research, professional development opportunities and assessments for the industry, designed to advance the art and science of admissions. Owned and administered by GMAC, the Graduate Management Admission Test® (GMAT®) is the most widely used graduate business school assessment, recognized by more than 7,000 programs worldwide. Other GMAC assessments include the NMAT by GMAC(TM) exam, for entrance into graduate management programs in India and South Africa, and the Executive Assessment, specifically designed for Executive programs around the world. Our flagship portal for graduate management education resources and information, www.mba.com, receives 14 million visits a year and features the School Search matching tool and Graduate Management Admission Search Service (GMASS), matching candidates and business schools.
GMAC is based in the United States with offices in the United Kingdom, India, and Hong Kong. To learn more about our work, please visit www.gmac.com.
Yolanda Kwok, Regional Director, Greater China, GMAC
Susanna Lee, Associate Director, Marketing, Greater China, GMAC
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Graduate Management Admission Council via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CEST | Pressemelding
CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients
Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CEST | Pressemelding
LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe
Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CEST | Pressemelding
Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle
iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CEST | Pressemelding
Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag
Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CEST | Pressemelding
MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad
Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CEST | Pressemelding
Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi